BSE 100 News and Updates

Pharmaceuticals company Lupin announced Q4FY25 & FY25 results Q4FY25 Financial Highlights: Gross Profit was Rs 38,760 million compared to Rs 33,213 million in Q4FY24, with a gross margin of 69.7%. Personnel cost was 18.0% of sales at Rs 10,013 million compared to Rs 9,002 million in Q4FY24. Manufacturing and other expenses were 30.3% of sales at Rs 16,876 million compared to Rs 14,901 million in Q4FY24. PBT at Rs 8,958 million at 16.1%, up 80.0% YoY from Rs 4,977 million in Q4FY24. Investment in R&D; for the quarter was Rs 5,346 million (9.6% of sales). FY25 Financial Highlights: Sales: Rs 2,21,921 million vs. Rs 1,96,563 million in FY24 — up 12.9% EBITDA: Rs 54,792 million vs. Rs 39,307 million in FY24 — up 39.4% EBITDA Margin: 24.7% vs. 20.0% in FY24 — up 469 bps PBT: Rs 40,150 million vs. Rs 24,223 million in FY24 — up 65.8% PAT: Rs 33,063 million vs. Rs 19,356 million in FY24 — up 70.8% Commenting on the results, Nilesh Gupta, Managing Director, Lupin said “We are delighted to end the last quarter and the year on a strong note. FY25 was led by strong growth in Sales and Profitability driven by in-line and new products, and consistent improvement in operating margins backed by strong commercial momentum and operational efficiencies. We are optimistic to continue this momentum in the year ahead” Result PDF

BSE 100 PB	4.1
BSE 100 PE	23.1
BSE 100 DIV	1.1
BSE 100 EPS	1,124.2

BSE 100 PB

BSE 100 PE

BSE 100 DIV

BSE 100 EPS

BSE 100 News and Updates

Keep track of all breaking news on BSE 100 from all sources in a single place.